Pilot Project 1
Johns Hopkins University, Baltimore MD
Investigators
Abstract
Prostate cancer is a leading cause of cancer-related death in men. Novel technologies can improve access to high-quality careâparticularly for patients at increased risk of aggressive disease or living in areas with a high prostate cancer burden. Current diagnostic methods, including PSA testing and biopsy, are often imprecise, leading to underdiagnosis and misclassification of disease severity. To address this, we propose a novel, non-invasive imaging modality using molecular chemical exchange saturation transfer (CEST) MRI on standard 3T scanners, combined with a machine learning-driven metabolic imaging processing pipeline. This technology will enable more accurate and cost-efficient detection and prognosis of prostate cancer aggressiveness. We aim to improve spatial resolution in molecular MRI using deep learning super-resolution models trained on simulated high-resolution metabolic images. These simulations will be derived from organ-scale vascular networks and metabolic conversion rates, allowing for subject-specific modeling of energy metabolism. Our specific aims include: 1. Mapping energy metabolism in aggressive prostate tumors using dynamic glucose-enhanced CEST MRI, 2. Developing a machine learning-based super-resolution model using subject-specific metabolic simulations, and 3. Validating patient-specific metabolic and perfusion models using clinical MRA and anatomical data. This pilot project contributes to the scientific priorities of H-H U54 by developing novel, scalable imaging technologies to improve prostate cancer detection and management, while also supporting research capacity in advanced molecular imaging and computational modeling across the partner institutions.
View original record on NIH RePORTER →